Agouron Pharmaceutical Rebounds, 1st-Period Profit Tops Estimates
Dow Jones Online News, Tuesday, April 14, 1998 at 17:42
Agouron Pharmaceuticals Inc. - La Jolla, Calif.
3rd Quar March 31:
1998 1997
Revenues a $134,458,000 $38,613,000
Net income 13,525,000 (4,999,000)
Avg shrs (basic) 30,757,000 27,230,000
Avg shrs (diluted) 32,956,000 27,230,000
Shr earns (basic)
Net income a .44 (.18)
Shr earns (diluted)
Net income a .41 (.18)
Figures in parentheses are losses.
a. Includes one-time revenues of $12 million from meeting certain
product approval milestones, adding earnings of about 22 cents a share.
The company released its earnings after the close of trading Tuesday.
A survey by First Call of nine analysts produced a mean earnings
estimate of 39 cents a share for the quarter.
Agouron Pharmacueticals (AGPH) said sales of its anti-HIV drug
Viracept were $112 million, including $92.8 million in the U.S., an
increase of 10% from the second quarter ended Dec. 31, 1997. The drug
was approved for marketing by the Food and Drug Administration in March
1997.
Copyright (c) 1998 Dow Jones & Company, Inc.
All Rights Reserved. |
